Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › IL › Wood Dale › NPI 1881630614
Lab

Quest Diagnostics LLC Il

Quest Diagnostics LLC Il was paid $429.84M by Medicaid between Jan 2018 and Dec 2024, across 569 billing codes. Its largest line is G0480, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed — 6.7% of everything it billed.

33Billing provider infoQUEST DIAGNOSTICS LLC IL
WOOD DALE, IL 60191
33aNPI1881630614assigned 06/21/2006
33bProvider typeClinical Medical Laboratory
28Total paid$429.84M
24GClaims29,324,170
24DCodes billed569
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other Clinical Medical Laboratory providers in Illinois

Rank by total paid#1 of 235
Median peer was paid$123K
This provider vs. median3,501×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Auditor's notes

Automated statistical signals. Not evidence of fraud — how these are computed.

Entity ProliferationAuthorized official TIMMERMAN, LEAH controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service

Paid by month

$0$5.0M$10M2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
20182,754,775$29.51M
20193,609,272$49.76M
20203,322,833$52.38M
20214,530,663$73.28M
20224,843,723$70.86M
20235,436,008$81.30M
2024incomplete4,826,896$72.75M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 6.7% 505,160 362,494 $28.87M
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 6.2% 364,169 308,045 $26.77M
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 6.1% 680,904 489,805 $26.04M
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe 5.7% 893,808 824,011 $24.35M
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe 5.6% 890,902 821,243 $24.23M
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies 4.9% 589,191 560,021 $20.94M
87801 Infectious agent detection by nucleic acid; amplified probe, multiple organisms 3.4% 319,251 294,246 $14.72M
84443 Thyroid stimulating hormone (TSH) 3.3% 1,247,639 1,178,325 $14.38M
80053 Comprehensive metabolic panel 3.0% 1,849,467 1,727,347 $12.99M
80061 Lipid panel 2.7% 1,523,071 1,446,476 $11.75M
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed 2.7% 748,731 708,189 $11.58M
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe 2.7% 532,730 497,859 $11.48M
557 more codes
81513 2.6% 169,387 $11.20M
80050 General health panel 2.3% 228,038 $9.90M
85025 Blood count; complete (CBC), automated, and automated differential WBC count 1.9% 1,700,467 $8.27M
87799 1.8% 220,620 $7.54M
86480 1.5% 148,912 $6.52M
83036 Hemoglobin; glycosylated (A1C) 1.5% 1,091,687 $6.47M
86803 1.1% 409,807 $4.74M
80081 1.1% 85,519 $4.59M
87624 Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types 1.1% 191,724 $4.58M
81420 Fetal chromosomal aneuploidy genomic sequence analysis panel 1.0% 10,751 $4.41M
88175 Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer <1% 232,250 $4.22M
87086 Culture, bacterial; quantitative colony count, urine <1% 647,545 $4.15M
86003 <1% 78,996 $4.00M
36415 Collection of venous blood by venipuncture <1% 1,395,984 $3.99M
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed <1% 42,217 $3.60M
87088 <1% 513,488 $3.47M
82607 <1% 358,031 $3.41M
80074 <1% 103,034 $3.26M
87512 <1% 118,503 $3.21M
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 <1% 136,068 $3.03M
83013 <1% 64,658 $2.39M
82728 <1% 272,549 $2.33M
84439 <1% 363,028 $2.32M
81220 CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants <1% 11,482 $2.15M
87536 <1% 36,106 $2.14M
88305 Level IV - Surgical pathology, gross and microscopic examination <1% 37,745 $2.13M
87340 <1% 226,728 $2.00M
82746 <1% 208,759 $1.97M
85027 <1% 410,176 $1.86M
83655 <1% 194,559 $1.82M
87902 <1% 10,805 $1.82M
87070 <1% 305,693 $1.77M
84153 <1% 138,826 $1.58M
86592 <1% 476,700 $1.55M
87522 Neg quan hep c or qual rna <1% 47,844 $1.49M
84403 <1% 82,933 $1.48M
83550 <1% 243,696 $1.44M
84702 <1% 145,300 $1.35M
86780 <1% 97,396 $1.30M
87636 Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B <1% 10,413 $1.29M
87186 <1% 185,158 $1.27M
83970 <1% 54,235 $1.27M
80048 Basic metabolic panel (calcium, ionized) <1% 224,686 $1.19M
83540 <1% 261,620 $1.18M
82570 <1% 318,172 $1.10M
81001 <1% 494,908 $1.10M
86235 <1% 24,708 $1.09M
86696 <1% 63,963 $1.05M
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed <1% 13,039 $974K
82043 <1% 270,320 $963K
82670 <1% 59,513 $959K
83001 <1% 69,957 $949K
86769 <1% 21,368 $925K
86038 <1% 97,286 $877K
86704 <1% 88,327 $859K
84481 <1% 80,756 $837K
84146 <1% 61,256 $785K
87081 <1% 158,283 $780K
86787 <1% 65,454 $728K
87077 <1% 140,721 $679K
86695 <1% 60,758 $674K
82105 <1% 49,854 $627K
86708 <1% 73,881 $619K
83002 <1% 54,151 $609K
86706 <1% 72,591 $603K
83735 <1% 132,198 $584K
88142 <1% 44,548 $575K
87480 <1% 38,180 $558K
87510 <1% 38,119 $556K
82652 <1% 27,881 $528K
83880 <1% 26,319 $507K
84402 <1% 30,490 $500K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe <1% 11,635 $492K
87660 <1% 37,564 $487K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed <1% 5,330 $486K
83690 <1% 93,986 $474K
88141 <1% 32,973 $469K
82785 <1% 52,052 $466K
86140 <1% 128,323 $460K
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets <1% 1,921 $450K
86376 <1% 45,444 $442K
87147 <1% 115,544 $437K
84550 <1% 142,094 $433K
86360 <1% 18,514 $427K
86008 <1% 8,087 $423K
86361 <1% 28,543 $406K
84144 <1% 30,832 $397K
87563 <1% 16,766 $391K
82150 <1% 80,216 $388K
87901 <1% 2,453 $386K
82784 <1% 41,720 $370K
81443 <1% 385 $362K
86762 <1% 40,809 $362K
82950 <1% 94,015 $347K
81511 <1% 6,179 $328K
86800 <1% 28,847 $316K
82627 <1% 24,033 $310K
82274 <1% 30,804 $307K
86317 <1% 37,245 $305K
84270 <1% 15,851 $302K
86200 <1% 35,274 $301K
84436 <1% 70,350 $293K
83520 <1% 30,682 $292K
86364 <1% 26,825 $288K
86060 <1% 44,402 $287K
81329 <1% 6,467 $286K
86431 <1% 66,056 $275K
87481 <1% 13,497 $270K
83525 <1% 34,499 $269K
80076 <1% 48,751 $269K
80362 <1% 29,748 $269K
86147 <1% 11,712 $267K
87631 <1% 2,875 $265K
85652 <1% 136,731 $264K
85610 <1% 95,157 $262K
83020 <1% 27,498 $259K
87900 <1% 2,480 $247K
86735 <1% 23,691 $244K
86850 <1% 41,142 $242K
87209 <1% 15,820 $230K
84480 <1% 30,907 $228K
80348 <1% 33,044 $223K
86665 <1% 10,126 $217K
83516 <1% 27,392 $216K
86146 <1% 8,252 $216K
83014 <1% 36,592 $213K
84479 <1% 52,846 $212K
87255 <1% 9,319 $212K
87625 <1% 9,619 $211K
86765 <1% 25,371 $209K
82951 <1% 21,351 $209K
84460 <1% 64,136 $203K
86336 <1% 13,549 $200K
82677 <1% 13,527 $195K
86160 <1% 15,821 $193K
87637 Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV <1% 1,458 $176K
86481 <1% 2,552 $176K
85730 <1% 42,857 $176K
84154 <1% 14,943 $173K
88342 <1% 4,325 $172K
87529 <1% 5,172 $170K
86225 <1% 18,780 $170K
83021 <1% 14,987 $169K
84450 <1% 55,556 $168K
84681 <1% 12,621 $167K
80164 <1% 21,523 $166K
86039 <1% 20,841 $159K
87338 <1% 12,356 $158K
80069 <1% 29,120 $157K
82533 <1% 13,751 $154K
80346 <1% 11,694 $153K
84425 <1% 10,314 $146K
82248 <1% 49,212 $145K
82550 <1% 35,197 $144K
84156 <1% 63,534 $143K
84100 <1% 49,854 $141K
87075 <1% 20,564 $140K
83498 <1% 8,158 $138K
80055 <1% 6,864 $135K
84703 <1% 22,757 $124K
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism <1% 4,861 $123K
87517 <1% 3,801 $122K
86812 <1% 7,488 $122K
85018 <1% 68,957 $122K
82565 <1% 42,109 $122K
80354 <1% 16,677 $117K
87177 <1% 15,911 $114K
80197 <1% 15,664 $113K
87906 <1% 1,259 $113K
G0475 Hiv antigen/antibody, combination assay, screening <1% 7,054 $110K
86747 <1% 3,574 $109K
86141 <1% 12,145 $109K
86334 <1% 7,290 $109K
86705 <1% 11,705 $105K
80355 <1% 13,740 $104K
83090 <1% 9,823 $102K
84165 <1% 13,888 $100K
86870 <1% 5,609 $99K
80349 <1% 18,828 $99K
86901 <1% 33,611 $99K
86593 <1% 30,282 $98K
82024 <1% 3,709 $97K
84445 <1% 2,821 $96K
82947 <1% 38,645 $96K
88112 <1% 2,968 $96K
86304 <1% 6,295 $96K
87427 <1% 10,582 $95K
82378 <1% 8,334 $94K
85660 <1% 23,575 $93K
81596 <1% 5,256 $92K
82672 <1% 6,425 $91K
80361 <1% 12,757 $90K
87449 <1% 10,155 $89K
80373 <1% 11,906 $88K
87045 <1% 11,360 $87K
G0103 Prostate cancer screening; prostate specific antigen test (psa) <1% 12,536 $86K
83721 <1% 16,757 $86K
83615 <1% 20,618 $85K
86900 <1% 33,562 $84K
85060 <1% 9,908 $83K
86664 <1% 7,452 $83K
86617 <1% 4,183 $82K
82977 <1% 18,453 $82K
80324 <1% 11,411 $81K
86618 <1% 6,593 $81K
84466 <1% 9,873 $81K
86709 <1% 11,560 $80K
85014 <1% 46,693 $79K
80366 <1% 10,400 $79K
86255 <1% 11,787 $78K
81025 <1% 15,605 $78K
86359 <1% 3,500 $77K
80353 <1% 11,789 $77K
82088 <1% 2,863 $74K
81003 <1% 47,217 $73K
83921 <1% 6,175 $70K
87650 <1% 3,580 $69K
86300 <1% 3,930 $69K
80178 <1% 15,585 $69K
87205 <1% 24,615 $68K
88304 <1% 2,769 $68K
82542 <1% 5,343 $67K
82330 <1% 8,041 $67K
84630 <1% 8,398 $67K
86341 <1% 4,157 $67K
82465 <1% 22,877 $66K
82310 <1% 21,686 $66K
80356 <1% 8,113 $61K
84207 <1% 3,534 $61K
83521 <1% 2,758 $60K
84134 <1% 6,276 $59K
86258 <1% 4,056 $57K
0241U Neonatal screening for hereditary disorders, genomic sequence analysis panel <1% 613 $56K
80321 <1% 9,893 $56K
84520 <1% 26,844 $56K
83993 <1% 4,420 $56K
80051 <1% 14,354 $55K
82040 <1% 18,842 $55K
82952 <1% 17,083 $53K
82247 <1% 16,286 $53K
82172 <1% 5,270 $52K
83704 <1% 3,071 $51K
85379 <1% 7,447 $49K
87804 Infectious agent antigen detection by immunoassay; Influenza, each type <1% 2,514 $49K
82140 <1% 5,712 $48K
87506 <1% 237 $47K
86021 <1% 5,598 $47K
85613 <1% 6,613 $47K
86162 <1% 3,626 $46K
86777 <1% 4,727 $46K
88312 <1% 909 $46K
87329 <1% 5,406 $46K
87324 <1% 5,253 $45K
83698 <1% 2,243 $45K
80365 <1% 10,560 $44K
84482 <1% 3,002 $43K
83718 <1% 7,910 $43K
85045 <1% 17,869 $42K
G0472 Hepatitis c antibody screening, for individual at high risk and other covered indication(s) <1% 4,519 $42K
86381 <1% 2,628 $42K
86778 <1% 3,218 $41K
82157 <1% 2,011 $40K
80177 <1% 5,522 $39K
85246 <1% 2,716 $39K
88185 <1% 152 $39K
84478 <1% 11,017 $39K
86645 <1% 3,401 $39K
87150 <1% 1,446 $38K
83695 <1% 4,686 $38K
82103 <1% 5,406 $38K
86702 <1% 4,392 $37K
82525 <1% 4,276 $37K
84075 <1% 11,994 $37K
84244 <1% 2,552 $36K
86701 <1% 4,401 $36K
85240 <1% 3,134 $36K
86301 <1% 2,445 $35K
84155 <1% 15,306 $34K
82668 <1% 2,902 $33K
81241 <1% 2,036 $33K
86644 <1% 3,473 $33K
87350 <1% 3,274 $33K
84182 <1% 317 $33K
87493 <1% 1,290 $32K
82164 <1% 3,522 $32K
86036 <1% 2,954 $32K
84305 <1% 2,354 $31K
82747 <1% 2,746 $31K
G0328 Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous <1% 4,730 $31K
82390 <1% 4,239 $30K
85245 <1% 2,172 $30K
85004 <1% 7,818 $30K
84432 <1% 2,629 $29K
84590 <1% 3,771 $29K
99199 Unlisted special service, procedure or report <1% 2,386 $28K
84166 <1% 2,664 $28K
88341 <1% 351 $28K
87535 <1% 1,144 $27K
81015 <1% 13,302 $27K
87651 Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe <1% 807 $27K
80159 <1% 2,912 $27K
87254 <1% 2,425 $27K
83519 <1% 2,459 $26K
86001 <1% 1,030 $26K
83010 <1% 3,389 $26K
85007 <1% 10,922 $25K
80156 <1% 3,365 $25K
82107 <1% 775 $24K
86337 <1% 1,563 $24K
85041 <1% 13,235 $24K
86707 <1% 2,955 $24K
82626 <1% 1,548 $24K
84484 <1% 3,218 $24K
86335 <1% 1,322 $24K
80299 <1% 1,900 $23K
99001 <1% 7,275 $23K
87076 <1% 4,088 $23K
80185 <1% 3,069 $22K
86015 <1% 2,752 $22K
84132 <1% 7,515 $22K
87046 <1% 5,509 $21K
82530 <1% 1,775 $21K
81243 <1% 1,141 $21K
82787 <1% 1,399 $21K
87101 <1% 3,945 $20K
83835 <1% 1,872 $20K
87102 <1% 3,602 $20K
80175 <1% 2,570 $20K
82085 <1% 3,154 $19K
83883 <1% 3,340 $18K
86355 <1% 757 $18K
80358 <1% 7,540 $18K
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A <1% 1,847 $18K
86308 <1% 4,705 $18K
87521 Neg quan hep c or qual rna <1% 867 $18K
85306 <1% 1,655 $17K
87497 <1% 741 $16K
83003 <1% 587 $16K
G0145 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision <1% 8,989 $16K
85247 <1% 1,081 $16K
82955 <1% 2,198 $15K
85048 <1% 9,415 $15K
88262 <1% 170 $14K
85303 <1% 1,590 $14K
86774 <1% 1,466 $14K
82642 <1% 643 $14K
86231 <1% 1,602 $14K
87040 <1% 1,709 $13K
82397 <1% 1,441 $13K
84295 <1% 4,653 $13K
87109 <1% 1,328 $13K
G0123 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision <1% 1,636 $13K
82175 <1% 956 $13K
85598 <1% 921 $12K
88230 <1% 184 $12K
81229 <1% 89 $12K
82232 <1% 1,733 $12K
87140 <1% 3,031 $12K
81240 <1% 744 $12K
82731 <1% 265 $12K
87106 <1% 1,911 $12K
83825 <1% 1,037 $12K
81270 <1% 267 $11K
80183 <1% 1,466 $11K
80202 <1% 1,290 $11K
86886 <1% 2,451 $11K
G0476 Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test <1% 575 $11K
80360 <1% 1,721 $11K
80165 <1% 1,431 $11K
84140 <1% 931 $11K
36416 <1% 6,673 $11K
82610 <1% 883 $10K
81381 <1% 231 $10K
85576 <1% 234 $10K
87507 <1% 42 $10K
86666 <1% 675 $10K
87185 <1% 2,572 $10K
80345 <1% 1,762 $10K
85597 <1% 773 $10K
80180 <1% 846 $10K
82435 <1% 3,698 $9K
84080 <1% 1,080 $9K
85300 <1% 1,157 $9K
86357 <1% 329 $9K
87220 <1% 2,732 $9K
86628 <1% 555 $9K
86682 <1% 1,008 $8K
82166 <1% 946 $8K
82104 <1% 873 $8K
82374 <1% 2,986 $8K
U0002 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc <1% 166 $8K
82679 <1% 516 $8K
87800 <1% 677 $8K
84260 <1% 507 $8K
84446 <1% 918 $8K
87210 <1% 1,468 $7K
89055 <1% 2,573 $7K
85384 <1% 1,247 $7K
83935 <1% 1,711 $7K
84300 <1% 2,253 $7K
87467 <1% 650 $7K
80184 <1% 1,003 $7K
86671 <1% 1,004 $7K
82553 <1% 1,034 $7K
87206 <1% 1,820 $7K
82653 <1% 408 $6K
87502 Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets <1% 115 $6K
81162 <1% 15 $6K
86606 <1% 370 $6K
G0124 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, requiring interpretation by physician <1% 1,030 $6K
83930 <1% 1,513 $6K
88307 <1% 39 $6K
83625 <1% 668 $6K
86738 <1% 462 $6K
84238 <1% 246 $5K
84255 <1% 330 $5K
87634 <1% 125 $5K
85397 <1% 213 $5K
82180 <1% 887 $5K
88184 <1% 153 $5K
80359 <1% 712 $5K
86753 <1% 867 $5K
86148 <1% 867 $5K
88189 <1% 119 $5K
82681 <1% 283 $4K
82575 <1% 688 $4K
81291 <1% 424 $4K
87328 <1% 408 $4K
82671 <1% 190 $4K
81512 <1% 93 $4K
80195 <1% 578 $4K
86648 <1% 324 $4K
82552 <1% 512 $4K
87107 <1% 683 $4K
87807 <1% 452 $3K
80369 <1% 621 $3K
85250 <1% 242 $3K
80323 <1% 805 $3K
82340 <1% 784 $3K
81279 <1% 44 $3K
84252 <1% 231 $3K
83992 <1% 564 $3K
85049 <1% 1,079 $3K
81256 <1% 128 $3K
86790 <1% 337 $3K
82384 <1% 161 $3K
80162 <1% 392 $3K
81401 <1% 139 $3K
83605 <1% 338 $3K
88344 <1% 13 $2K
86698 <1% 125 $2K
81374 <1% 281 $2K
86880 <1% 508 $2K
81479 Unlisted molecular pathology procedure <1% 215 $2K
85670 <1% 463 $2K
86256 <1% 241 $2K
81339 <1% 27 $2K
83876 <1% 80 $2K
80158 <1% 170 $2K
84133 <1% 551 $1K
80372 <1% 640 $1K
87425 <1% 146 $1K
86382 <1% 62 $1K
80186 <1% 161 $1K
87272 <1% 133 $1K
87581 <1% 43 $1K
86609 <1% 150 $1K
80342 <1% 31 $911.64
87420 <1% 95 $852.75
86663 <1% 74 $760.34
86710 <1% 42 $693.95
84591 <1% 61 $683.85
89060 <1% 125 $679.02
89051 <1% 168 $607.79
82365 <1% 83 $581.08
81257 <1% 31 $551.73
86692 <1% 48 $524.12
84145 <1% 29 $501.14
82985 <1% 71 $495.38
86905 <1% 97 $488.47
80338 <1% 42 $455.04
80374 <1% 57 $443.85
82239 <1% 40 $431.86
80503 <1% 26 $419.51
86635 <1% 34 $339.00
82657 <1% 18 $317.19
84597 <1% 41 $308.75
86340 <1% 30 $290.78
86757 <1% 18 $287.90
87015 <1% 58 $276.45
84163 <1% 22 $267.31
81232 <1% 29 $263.05
81230 <1% 30 $263.05
81231 <1% 27 $263.05
86041 <1% 27 $250.40
80320 <1% 36 $244.97
85230 <1% 14 $244.44
85220 <1% 14 $226.58
80201 <1% 31 $206.56
80235 <1% 26 $201.10
82705 <1% 65 $200.09
85549 <1% 14 $194.14
G0306 Complete cbc, automated (hgb, hct, rbc, wbc, without platelet count) and automated wbc differential count <1% 89 $179.97
87230 <1% 13 $174.87
84560 <1% 53 $173.06
86612 <1% 16 $159.01
80332 <1% 34 $154.59
86631 <1% 22 $154.01
86316 <1% 12 $151.25
85307 <1% 13 $149.79
87168 <1% 50 $145.95
83874 <1% 16 $144.65
85305 <1% 27 $143.36
83630 <1% 13 $136.80
82941 <1% 12 $130.78
85335 <1% 13 $128.70
80368 <1% 20 $120.56
83945 <1% 12 $119.77
82608 <1% 14 $117.06
84202 <1% 12 $115.92
81400 <1% 34 $106.34
84378 <1% 13 $99.52
83631 <1% 13 $96.30
88300 <1% 12 $93.83
86632 <1% 15 $92.53
80157 <1% 13 $91.62
85651 <1% 40 $89.11
80377 <1% 18 $80.28
86331 <1% 12 $75.72
87172 <1% 21 $66.70
82160 <1% 12 $59.44
80367 <1% 19 $53.05
87207 <1% 15 $47.93
84105 <1% 13 $47.61
82595 <1% 13 $44.99
89190 <1% 12 $38.32
82436 <1% 13 $34.20
83986 <1% 12 $32.89
81350 <1% 19 $19.17
87999 <1% 29 $17.96
3050F 0% 6,978 $0.00
0001M 0% 79 $0.00
3051F 0% 865 $0.00
3046F 0% 769 $0.00
81247 0% 16 $0.00
80370 0% 18 $0.00
81328 0% 16 $0.00
81335 0% 19 $0.00
81355 0% 19 $0.00
80337 0% 18 $0.00
3052F 0% 531 $0.00
3048F 0% 15,872 $0.00
3049F 0% 9,634 $0.00
3044F 0% 23,010 $0.00
80335 0% 19 $0.00
81283 0% 16 $0.00
81227 0% 18 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialTIMMERMAN, LEAH (VICE PRESIDENT)
Parent organizationQUEST DIAGNOSTICS INCORPORATED
Same official

Other billing entities under TIMMERMAN, LEAH

Full network →
ProviderLocationPaid
Unilab CorporationWest Hills, CA$668.50M
Quest Diagnostics IncorporatedClifton, NJ$637.74M
Quest Diagnostics Clinical Laboratories INCIrving, TX$276.76M
Labone LLCLenexa, KS$212.28M
Quest Diagnostics Clinical Laboratories INCTucker, GA$211.13M
Quest Diagnostics Clinical Laboratories INCMiramar, FL$197.58M
Labone of Ohio INCCincinnati, OH$167.17M
Unilab CorporationSacramento, CA$141.24M
Quest Diagnostics Incorporated MDBaltimore, MD$121.81M
Quest Diagnostics IncorporatedLas Vegas, NV$59.32M
Quest Diagnostics LLC IlSchaumburg, IL$50.71M
Quest Diagnostics Clinical Laboratories INCTampa, FL$49.99M
Quest Diagnostics Nichols Institute, INC.Chantilly, VA$46.91M
Quest Diagnostics Nichols InstituteSan Juan Capistrano, CA$39.93M
Quest Diagnostics Clinical Laboratories INCNorristown, PA$22.72M
Specialty Laboratories INCWest Hills, CA$16.76M
Quest Diagnostics Clinical Laboratories INCDenver, CO$14.27M
Quest Diagnostics Clinical Laboratories INCHouston, TX$8.76M
Med Fusion, LLCLewisville, TX$4.17M
Quest Diagnostics Clinical Laboratories INCMaryland Heights, MO$2.98M

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.